Sagimet Biosciences SGMT

David Happel has served as our Chief Executive Officer and a director since October 2022. From March 2020 through October 2022, he was President and Chief Executive Officer, and a director on the board of Cognoa, Inc., a pediatric behavioral health company developing AI-based technologies for developmental and behavioral health conditions, including the first FDA-authorized diagnostic aid, Canvas Dx, for autism. From February 2018 to March 2020, Mr. Happel was President, Chief Executive Officer and a director on the board of Chrono Therapeutics Inc. In addition, Mr. Happel has served as a director of Currax Pharmaceuticals LLC since 2020 and he previously held several executive and commercial positions at Horizon Therapeutics plc, or Horizon, Raptor Pharmaceutical Corp., Dynavax Technologies Corporation and Chiron Corporation. Mr. Happel also currently sits on the board of a privately held company. Mr. Happel has a B.A. in chemistry from Indiana University and an M.B.A. from Indiana State University.

Elizabeth Rozek, Esq. has served as our Chief Legal and Administrative Officer since November 2025. Prior to this role, she served as our General Counsel and Chief Compliance Officer from April 2023 to November 2025. From December 2020 to December 2022, Ms. Rozek served as General Counsel and Chief Compliance Officer of Cognoa, Inc. From January 2010 to April 2023, she held various counsel positions at Basilea Pharmaceutica International Ltd., a Swiss-listed biopharmaceutical company with global operations, including Litigation Counsel (January 2010 to July 2010), General Counsel and Corporate Secretary (March 2011 to July 2017), Advisory External Counsel (August 2017 to December 2020), and Consultant (December 2020 to April 2023). From 2001 to 2006, Ms. Rozek served as a civil prosecutor for the U.S. Department of Justice. Ms. Rozek received her B.A. in literature from Brown University, M.A. in literature from the University of California at San Diego and J.D. from the University of California at Berkeley.

Beth Seidenberg, M.D. has served as a member of our Board since April 2007 and was appointed our Board's Lead Independent Director in May 2025. Dr. Seidenberg serves as a Managing Director of Westlake BioPartners, a life sciences venture capital firm she founded in September 2018. Since May 2005, Dr. Seidenberg has served as a general partner at Kleiner Perkins Caufield & Byers, LLC, where she has primarily focused on life science investing. Dr. Seidenberg was previously the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen Inc. Previously, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company and Merck & Co., Inc. Dr. Seidenberg received a B.A. in biology and anthropology from Barnard College and an M.D. from the University of Miami School of Medicine and completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health. Dr. Seidenberg currently serves on the boards of directors of Vera Therapeutics, Inc. (Nasdaq: VERA) and Kyverna Therapeutics, Inc. (Nasdaq: KYTX); positions she has held since June 2016 and September 2018, respectively. Dr. Seidenberg also serves on the board of directors of several privately held life sciences companies. She previously served on the board of directors of Acelyrin, Inc. (acquired by Alumis; (Nasdaq: SLRN)) from October 2020 until May 2025, Progyny, Inc. from May 2010 until November 2025, and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) from August 2012 until June 2023.

Paul Hoelscher has served as a member of our Board since April 2024. Mr. Hoelscher served as Executive Vice President and Chief Financial Officer of Horizon, from 2014 until his retirement in May 2022, overseeing all aspects of Horizon's financial operations. Prior to joining Horizon, Mr. Hoelscher held financial executive positions at OfficeMax, Inc., or OfficeMax, a business services company, from 2012 to 2014, including serving as Senior Vice President, Finance, Treasury and Corporate Development and co-leading the integration of OfficeMax and Office Depot Inc. Previously, Mr. Hoelscher held various financial leadership roles of increasing responsibility over nineteen years at Alberto Culver Company, a beauty care company, and worked in the audit practice of KPMG for seven years. Mr. Hoelscher received his B.S. in accountancy from the University of Illinois at Urbana-Champaign and is a certified public accountant. Mr. Hoelscher served on the board of Reneo Pharmaceuticals, Inc. (now OnKure Therapeutics, Inc. (Nasdaq: OKUR)), a public pharmaceutical company, from January 2022 to October 2024, and served on the board of trustees of the Illinois Region of The Leukemia & Lymphoma Society from 2007 to 2022, including two terms as board chair.

Elizabeth Grammer, Esq. has served as a member of our Board since April 2021. Currently, Ms. Grammer serves as a Senior Advisor of Ardelyx, Inc., or Ardelyx. From January 2020 to December 2025, she served as the Chief Legal and Administrative Officer of Ardelyx. From May 2014 to January 2020, she served as the General Counsel of Ardelyx and from December 2012 until May 2014, she served as the Vice President of Legal Affairs. From 2006 to December 2012, Ms. Grammer served as an independent outside corporate counsel for public and private biotechnology companies. From 2001 to 2006, Ms. Grammer served as Vice President and General Counsel of Trine Pharmaceuticals, Inc., a biopharmaceutical company. In addition, Ms. Grammer previously served as independent outside corporate counsel to GelTex Pharmaceuticals Inc, a biopharmaceutical company. Ms. Grammer also previously served on the board of directors of the California Life Sciences Association from 2018 to 2021. Ms. Grammer received a B.A. in political science from Boston University and a J.D. from Stanford Law School.

George Kemble, Ph.D. has served as a director since October 2015 and as Chairman of the Board since May 2025. From October 2022 until May 2025 he served as our Executive Chairman of the Board. He previously served as our Chief Executive Officer from October 2015 through October 2022, in addition to serving as our Chief Scientific Officer from August 2011 through October 2022. From 2001 through 2011, he held various leadership positions at MedImmune LLC, a biologics company and subsidiary of AstraZeneca PLC, including Vice President of Research & Development for Vaccines, Senior Vice President of Research for Biologics and General Manager of the California operations. Early in his career, from 1993 until 2001, he was a research scientist at Aviron Ltd. focusing on viral vaccine technologies. He received his B.S. in biology from Santa Clara University, a Ph.D. from Stanford University from the department of microbiology and immunology and held a postdoctoral research fellowship at University of California, San Francisco.

Jennifer Jarrett has served as a member of our Board since August 2024. Ms. Jarrett currently serves as the President, Chief Executive Officer and board director at Damora Therapeutics (Nasdaq: DMRA). From 2021 until March 2026, she served as Chief Operating Officer of Arcus Biosciences, Inc., or Arcus, a clinical-stage, global biopharmaceutical company, and previously served on the board of directors of Arcus from January 2019 until January 2024. Prior to joining Arcus as Chief Operating Officer, Ms. Jarrett served as Vice President, Corporate Development and Capital Markets at Uber, Inc., a technology company providing a platform for mobility, delivery and freight services, from January 2019 to 2021 and prior to that, served as Arcus' Chief Operating and Financial Officer from March 2017 to January 2019. From April 2016 to October 2016, Ms. Jarrett was the Chief Financial Officer of Medivation, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. Prior to that, Ms. Jarrett spent 20 years in investment banking, most recently as Managing Director at Citigroup from July 2010 to March 2016, where she was responsible for managing their west coast life sciences investment banking practice. Ms. Jarrett currently serves on the board of directors of Damora Therapeutics, Zura Bio Ltd (Nasdaq: ZURA), Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), and LifeMine Therapeutics, Inc. Ms. Jarrett previously served on the boards of directors of Arena Pharmaceuticals, Inc. from July 2017 until its acquisition by Pfizer in March 2022, Audentes Therapeutics from July 2017 until its acquisition by Astellas Pharma Inc. in January 2020, Radius Health, Inc. from May 2022 until its acquisition by Gurnet Point Capital and Patient Square Capital in August 2022, and Consonance-HFW Acquisition Corp. from December 2020 until its business combination with Surrozen Operating, Inc. in August 2021. Ms. Jarrett holds a B.A. in Economics, cum laude, from Dartmouth College and an M.B.A. from Stanford Graduate School of Business.

Anne Phillips, M.D. has served as a member of our Board since August 2024. Dr. Phillips has over 25 years of pharmaceutical industry experience. Ms. Phillips joined our Board following a tenure at Novo Nordisk A/S, or Novo Nordisk, a global healthcare company, where she most recently served as a Senior Vice President of Clinical, Medical & Regulatory Affairs, North America Operations, leading the drug development, clinical operations, medical, regulatory, health economics and outcomes research, and safety teams, from January 2011 to August 2022. Prior to joining Novo Nordisk, Dr. Phillips held positions of increasing seniority at GSK plc from 1998 to 2004, most recently as Vice President and Head of R&D. Dr. Phillips currently serves on the board of directors of Barinthus Biotherapeutics plc (Nasdaq: BRNS), a clinical-stage biopharmaceutical company, a position she has held since February 2021, and most recently, vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage public biopharmaceutical company, whose board she joined in March 2024. Dr. Phillips previously served as a member of the board of directors of Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, from December 2014 to November 2024, Carmot Therapeutics Inc., a biopharmaceutical company, from September 2022 to December 2023, when it was acquired by F. Hoffmann-La Roche AG and AMAG Pharmaceuticals, Inc., a pharmaceutical company, from April 2019 to November 2020. Dr. Phillips received an Hon. B.Sc. in Zoology from the University of Western Ontario and an M.D. from the University of Toronto. She completed postgraduate training in Internal Medicine, Medical Microbiology and Infectious Diseases.

Thierry Chauche has served as our Chief Financial Officer since May 2024. Mr. Chauche has over 25 years of financial and operational leadership experience in finance and healthcare companies. He previously served as the Chief Financial Officer of Provention Bio, Inc., from December 2021 until it was acquired by Sanofi S.A. in April 2023. From 2021 to 2021, Mr. Chauche served as the Vice President and Head of Strategic Financial Planning & Analysis at Alexion Pharmaceuticals, Inc. Prior to this, Mr. Chauche served in roles of increasing responsibility at Intercept Pharmaceuticals, Inc. from 2017 to 2020, Novartis AG from 2007 to 2017, and Rothschild & Cie from 1999 to 2005. Mr. Chauche holds an M.S. in engineering from Ecole Des Ponts ParisTech and an MBA from the Wharton School of the University of Pennsylvania.

Andreas Grauer, M.D. has served as our Chief Medical Officer since April 2026. Prior to this role, Dr. Grauer most recently served as Chief Medical Officer at Omeros Corporation (NASDAQ: OMER) from October 2023 to April 2026. Prior to Omeros, Dr. Grauer held Chief Medical Officer roles at Federation Bio (October 2021 to July 2023) and Corcept Therapeutics Incorporated (March 2019 to August 2021). Prior to these roles, Dr. Grauer held various positions at Amgen, Inc. (December 2008 to December 2018) including Vice President Global Development. Dr. Grauer began his career at Procter & Gamble Pharmaceuticals (1999 to November 2008). Dr. Grauer continues to serve as an Associate Professor of Medicine at the University of Heidelberg Medical School, Germany, where he received his M.D. and also completed his clinical training in internal medicine and endocrinology.